VITAL BRIEFING: Senate passes bill to limit patents asserted against biosimilars applicants

The Senate has passed bipartisan legislation to limit patent assertions against biosimilars applicants, accelerating approval and market entry of lower-cost alternatives to branded biologic drugs; the bill now moves to the House.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.